ES2514140A1 - Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento - Google Patents

Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento Download PDF

Info

Publication number
ES2514140A1
ES2514140A1 ES201330436A ES201330436A ES2514140A1 ES 2514140 A1 ES2514140 A1 ES 2514140A1 ES 201330436 A ES201330436 A ES 201330436A ES 201330436 A ES201330436 A ES 201330436A ES 2514140 A1 ES2514140 A1 ES 2514140A1
Authority
ES
Spain
Prior art keywords
inhibitor
stx64
treating aging
steroid
sulfatases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330436A
Other languages
English (en)
Other versions
ES2514140B1 (es
Inventor
Manuel Jesús MUÑOZ RUIZ
María Mercedes PÉREZ JIMÉNEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Pablo de Olavide
Original Assignee
Universidad Pablo de Olavide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Pablo de Olavide filed Critical Universidad Pablo de Olavide
Priority to ES201330436A priority Critical patent/ES2514140B1/es
Priority to US14/907,658 priority patent/US20160361244A1/en
Priority to PCT/ES2014/070230 priority patent/WO2014154927A1/es
Priority to EP14775264.6A priority patent/EP3011950A4/en
Publication of ES2514140A1 publication Critical patent/ES2514140A1/es
Application granted granted Critical
Publication of ES2514140B1 publication Critical patent/ES2514140B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento. La presente invención se refiere al uso del inhibidor de la actividad de la enzima sulfatasa esteroidea STX64 para el tratamiento del envejecimiento y, por tanto, para incrementar la longevidad de los individuos o mejorar la calidad de vida de éstos. También se refiere a una composición cosmética que comprenda dicho inhibidor con ese fin.

Description

imagen1

Claims (1)

  1. imagen1
ES201330436A 2013-03-26 2013-03-26 Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento Active ES2514140B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201330436A ES2514140B1 (es) 2013-03-26 2013-03-26 Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento
US14/907,658 US20160361244A1 (en) 2013-03-26 2014-03-26 Use of the inhibitor of steroid sulfatases stx64 for treating aging
PCT/ES2014/070230 WO2014154927A1 (es) 2013-03-26 2014-03-26 Uso del inhibidor de sulfatasas esteroideas stx64 para el tratamiento del envejecimiento
EP14775264.6A EP3011950A4 (en) 2013-03-26 2014-03-26 Use of the inhibitor of steroid sulfatases stx64 for treating aging

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330436A ES2514140B1 (es) 2013-03-26 2013-03-26 Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento

Publications (2)

Publication Number Publication Date
ES2514140A1 true ES2514140A1 (es) 2014-10-27
ES2514140B1 ES2514140B1 (es) 2015-08-03

Family

ID=51622473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330436A Active ES2514140B1 (es) 2013-03-26 2013-03-26 Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento

Country Status (4)

Country Link
US (1) US20160361244A1 (es)
EP (1) EP3011950A4 (es)
ES (1) ES2514140B1 (es)
WO (1) WO2014154927A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
EP3810128B1 (en) * 2018-06-19 2022-08-03 Universidad Pablo de Olavide Compositions for treating and/or preventing protein-aggregation diseases
KR102162633B1 (ko) * 2019-03-13 2020-10-07 연세대학교 산학협력단 비만 또는 지질 관련 대사성 질환의 예방 또는 치료용 조성물
EP3988095A1 (en) * 2020-10-26 2022-04-27 Universidad Pablo de Olavide Sulfated c19 steroid hormones to extend lifespan and protect against aging-associated proteotoxicity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531048T2 (de) 1994-04-05 2004-05-06 Celltech Therapeutics Ltd., Slough Verwendung von steroidsulphatase-hemmern
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
JP4320089B2 (ja) 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
CA2501556A1 (en) 2002-10-09 2004-04-29 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
GB0511190D0 (en) * 2005-06-01 2005-07-06 Sterix Ltd Use
GB0624105D0 (en) * 2006-12-01 2007-01-10 Sterix Ltd Use
BRPI0811102A2 (pt) * 2007-05-15 2014-09-23 Puretech Ventures Métodos e composições para tratar condições de pele
AU2010236016A1 (en) * 2010-02-01 2011-08-18 Peter Maccallum Cancer Institute Method of treatment of EGFR inhibitor toxicity

Also Published As

Publication number Publication date
ES2514140B1 (es) 2015-08-03
EP3011950A4 (en) 2017-03-15
EP3011950A1 (en) 2016-04-27
WO2014154927A1 (es) 2014-10-02
US20160361244A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112018074979A2 (pt) composições de limpeza que compreendem enzimas
EP3957711A3 (en) Detergent composition comprising amylase and protease variants
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
UY34645A (es) Control de microorganismos fitopatogénicos con pseudomonas sp. y sustancias y composiciones derivad as de las mismas
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
TR201900319T4 (tr) C1 esteraz inhibitör eksikliği ile ilişkili bozuklukların önlenmesinde ve tedavisinde kullanım için c1-inh bileşimleri ve yöntemler.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
UY34050A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol- 2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2514140

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150803